Drug development firm Targacept has filed plans with the Securities and Exchange Commission to sell $75 million in stock.

Targacept (NASDAQ; TRGT) said funds from the sale would be used “to fund our operations and for other general corporate purposes, such as working capital, development of our clinical and preclinical product candidates, intellectual property protection and enforcement, capital expenditures, investments and acquisitions.”

Targacept’s lead drug candidate targets Alzheimer’s.

Targacept shares traded at $9.51 on Monday.